MGTX:NASDAQMeiraGTx Holdings plc Analysis

MeiraGTx (MGTX) is trading at $9.60, just above its 20‑day SMA of $9.52 but slightly below the 50‑day SMA of $9.61, indicating a modest short‑term pull‑back within a neutral trend. The RSI sits at 52, suggesting neither overbought nor oversold conditions, while the MACD remains bearish with the line below the signal, reinforcing downside pressure. Volatility is elevated at ~55% over the past 30 days and beta is high at 1.94, pointing to a stock that moves sharply with the market. Fundamental metrics are weak: the company posted a Q1 loss of $0.57 per share, missing consensus by over 30%, and operates with negative operating margins and a negative PE ratio. Nonetheless, the DCF fair‑value estimate of $6.17 is well below the current price, implying the market is pricing in significant future upside from its gene‑therapy pipeline, especially after receiving FDA Breakthrough Therapy Designation for AAV2‑hAQP1. The balance sheet shows $71.5 M cash offset by $87.5 M debt, and free cash flow remains positive, providing some runway. Support sits at $8.89 and resistance at $10.71, with volume trending down, suggesting limited buying pressure. Overall, the stock is overvalued relative to intrinsic estimates but could benefit from upcoming clinical milestones.